Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm BayStreet.ca - Fri Oct 20, 2023

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 221.55 (+0.58%)
NYT : 52.30 (+0.62%)
ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
MACK : 15.13 (unch)
INCY : 57.66 (-2.30%)
MRTX : 58.70 (-0.17%)
BNTX : 79.86 (+1.40%)
Pancreatic Cancer Battle Boosted by $200M VC Firm PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

ONC.TO : 1.41 (+2.92%)
ONCY : 1.0100 (+2.02%)
MACK : 15.13 (unch)
INCY : 57.66 (-2.30%)
MRTX : 58.70 (-0.17%)
BNTX : 79.86 (+1.40%)
Pancreatic Cancer Battle Boosted by $200M VC Firm FinancialNewsMedia - Tue Sep 19, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

AAPL : 221.55 (+0.58%)
ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
MACK : 15.13 (unch)
INCY : 57.66 (-2.30%)
MRTX : 58.70 (-0.17%)
BNTX : 79.86 (+1.40%)
Merrimack Reports First Quarter 2023 Financial Results Business Wire - Thu May 4, 2023

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.

MACK : 15.13 (unch)
Merrimack Reports Full Year 2022 Financial Results Business Wire - Thu Mar 9, 2023

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.

MACK : 15.13 (unch)
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan Business Wire - Mon Dec 5, 2022

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss...

MACK : 15.13 (unch)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer BayStreet.ca - Tue Nov 15, 2022

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
SGEN : 228.74 (-0.07%)
MRTX : 58.70 (-0.17%)
AMGN : 309.38 (-0.45%)
MACK : 15.13 (unch)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer FinancialNewsMedia - Tue Nov 15, 2022

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
SGEN : 228.74 (-0.07%)
MRTX : 58.70 (-0.17%)
AMGN : 309.38 (-0.45%)
MACK : 15.13 (unch)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer FinancialNewsMedia - Thu Nov 10, 2022

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
MACK : 15.13 (unch)
NRBO : 4.47 (-4.48%)
MRK : 125.85 (-1.46%)
RNAZ : 0.8681 (-7.65%)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer PR Newswire - Thu Nov 10, 2022

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

ONC.TO : 1.41 (+2.92%)
ONCY : 1.0100 (+2.02%)
MACK : 15.13 (unch)
NRBO : 4.47 (-4.48%)
MRK : 125.85 (-1.46%)
RNAZ : 0.8681 (-7.65%)

Barchart Exclusives

3 Mid-Cap Energy Dividend Stocks to Scoop Up Now Barchart - Wed Jul 3, 6:30PM CDT
Amid predictions of higher oil prices, here are three dividend-paying energy stocks that are worth adding to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot